Trial intelligence / Profile preview

Remodulin in Primary Pulmonary Hypertension

NCT00004497Phase 3Completed

Sponsor
United Therapeutics Corporation
Start
Oct 1998
Modality
Orthosteric Ligands
Countries
1
01

Overview

A Phase 3 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Oct 1998; status: completed.

02

Drugs

treprostinil
03

Conditions

pulmonary arterial hypertension (PAH)

Beyond the preview

Go deeper on NCT00004497.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00004497.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call